Candidemia - Pipeline Insight - 2020
This report can be delivered to the clients within 48-72 Hours
DelveInsight’s, “Candidemia – Pipeline Insight, 2020,” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Candidemia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Candidemia: Overview
Candidemia is defined as the presence of Candida species in the blood. It is the most common fungal bloodstream infection in hospitalized patients. Candida albicans is the most common cause of candidemia, representing 35% to 60% of isolates. Candida parapsilosis, Candida tropicalis, Candida glabrata and Candida krusei, are the most common nonalbicans Candida species identified in cultures. Most common risk factors include critical illness and prolonged intensive care unit stay. The presence of a central venous catheter, antibiotic exposure, abdominal surgery (especially if repeated laparotomies or anastomotic leakage is present), malignancy (solid organ and hematologic), acute necrotizing pancreatitis, organ transplant recipients, and total parenteral nutrition are other major risk factors.
Symptoms
The symptoms of Candidemia include:
Diagnosis of candidemia is based on direct fungal detection in blood cultures. The advantage of cultures is the ability to do susceptibility testing. Biopsy should be done in patients with localized findings and sent for culture and gram staining. The diagnosis can also be made by detecting antigens of Candida in the blood stream. New polymerase chain reaction tests are being developed and evaluated in clinical trials.
Treatment
Early empiric antifungal therapy should be strongly considered in critically ill patients with risk factors for invasive candidiasis in whom the disease is suspected, as some studies have shown reduced mortality with this strategy. The decision to start therapy should be based on clinical suspicion, risk factors, and surrogate markers of candidemia (e.g., B-d-glucan). Empiric therapy should start with an echinocandin (caspofungin, micafungin, anidulafungin) as first choice therapy. Fluconazole may be considered in certain patients who are not critically ill and in whom susceptibility to fluconazole is likely. Amphotericin B can be given to patients with intolerance or contraindications to other treatments. Transition to fluconazole is recommended for stable patients in whom cultures have resulted in sensitive Candida species, such as C. albicans.
Candidemia Emerging Drugs Chapters
This segment of the Candidemia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Candidemia Emerging Drugs
Further product details are provided in the report
Candidemia: Therapeutic Assessment
This segment of the report provides insights about the different Candidemia drugs segregated based on following parameters that define the scope of the report, such as:
Candidemia: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Candidemia therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Candidemia drugs.
Report Highlights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Candidemia – Pipeline Insight, 2020,” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Candidemia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Candidemia: Overview
Candidemia is defined as the presence of Candida species in the blood. It is the most common fungal bloodstream infection in hospitalized patients. Candida albicans is the most common cause of candidemia, representing 35% to 60% of isolates. Candida parapsilosis, Candida tropicalis, Candida glabrata and Candida krusei, are the most common nonalbicans Candida species identified in cultures. Most common risk factors include critical illness and prolonged intensive care unit stay. The presence of a central venous catheter, antibiotic exposure, abdominal surgery (especially if repeated laparotomies or anastomotic leakage is present), malignancy (solid organ and hematologic), acute necrotizing pancreatitis, organ transplant recipients, and total parenteral nutrition are other major risk factors.
Symptoms
The symptoms of Candidemia include:
- Fever, chills
- Skin rash
- Generalized weakness or fatigue
- Low blood pressure
- Muscle aches
- Vision changes or signs of an eye infection
- Headaches and neurological deficits
- Abdominal pain
Diagnosis of candidemia is based on direct fungal detection in blood cultures. The advantage of cultures is the ability to do susceptibility testing. Biopsy should be done in patients with localized findings and sent for culture and gram staining. The diagnosis can also be made by detecting antigens of Candida in the blood stream. New polymerase chain reaction tests are being developed and evaluated in clinical trials.
Treatment
Early empiric antifungal therapy should be strongly considered in critically ill patients with risk factors for invasive candidiasis in whom the disease is suspected, as some studies have shown reduced mortality with this strategy. The decision to start therapy should be based on clinical suspicion, risk factors, and surrogate markers of candidemia (e.g., B-d-glucan). Empiric therapy should start with an echinocandin (caspofungin, micafungin, anidulafungin) as first choice therapy. Fluconazole may be considered in certain patients who are not critically ill and in whom susceptibility to fluconazole is likely. Amphotericin B can be given to patients with intolerance or contraindications to other treatments. Transition to fluconazole is recommended for stable patients in whom cultures have resulted in sensitive Candida species, such as C. albicans.
Candidemia Emerging Drugs Chapters
This segment of the Candidemia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Candidemia Emerging Drugs
- Rezafungin acetate: Cidara Therapeutics
- Fosmanogepix: Amplyx Pharmaceuticals
Further product details are provided in the report
Candidemia: Therapeutic Assessment
This segment of the report provides insights about the different Candidemia drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Candidemia
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- intravitreal
- Subretinal
- Topical.
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Candidemia: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Candidemia therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Candidemia drugs.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Candidemia R&D. The therapies under development are focused on novel approaches to treat/improve Candidemia.
- Candidemia Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Candidemia drugs?
- How many Candidemia drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Candidemia?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Candidemia therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Candidemia and their status?
- What are the key designations that have been granted to the emerging drugs?
- Cidara Therapeutics
- Amplyx Pharmaceuticals
- Rezafungin acetate
- Fosmanogepix
Introduction
Executive Summary
Candidemia: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Candidemia – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Candidemia companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Candidemia Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Rezafungin acetate: Cidara Therapeutics
Product Description
Research and Development
Product Development Activities
Mid Stage Products (Phase II)
Comparative Analysis
Fosmanogepix: Amplyx Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Early Stage Products (Phase I)
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Pre-clinical and Discovery Stage Products
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Inactive Products
Comparative Analysis
Candidemia Key Companies
Candidemia Key Products
Candidemia- Unmet Needs
Candidemia- Market Drivers and Barriers
Candidemia- Future Perspectives and Conclusion
Candidemia Analyst Views
Candidemia Key Companies
Appendix
Executive Summary
Candidemia: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Candidemia – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Candidemia companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Candidemia Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Rezafungin acetate: Cidara Therapeutics
Product Description
Research and Development
Product Development Activities
Mid Stage Products (Phase II)
Comparative Analysis
Fosmanogepix: Amplyx Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Early Stage Products (Phase I)
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Pre-clinical and Discovery Stage Products
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Inactive Products
Comparative Analysis
Candidemia Key Companies
Candidemia Key Products
Candidemia- Unmet Needs
Candidemia- Market Drivers and Barriers
Candidemia- Future Perspectives and Conclusion
Candidemia Analyst Views
Candidemia Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Candidemia
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Candidemia
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Candidemia
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Candidemia
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
